Regression of melanoma xenografts by neutron capture therapy

Simple item page
dc.contributor.authorBuck, Sen_AU
dc.contributor.authorAllen, BJen_AU
dc.date.accessioned2025-12-01T06:30:19Zen_AU
dc.date.available2025-12-01T06:30:19Zen_AU
dc.date.issued1989-09-22en_AU
dc.date.statistics1989-11-12en_AU
dc.descriptionPhysical copy held by ANSTO Library at DDC: 571.45/14en_AU
dc.description.abstractThe development of Neutron Capture Therapy (NCT) offers advantages to conventional radiation therapy which is limited by the tolerance of surrounding healthy tissues within the treatment volume. NCT also eliminates the problems associated with radioisotope label led anti—tumour agents in that there is no initial radiation dose to whole body prior to selective tumour targeting, and no longer term background effect to normal tissues. NCT utilizes 10B (n, α) 7Li reaction in order to deposit short range (10—14μm) high linear Energy Transfer (LET) radiation of an average 2.4 MeV, within a tumour mass . The efficacy of this technique relies upon an adequate 10B distribution within the tumour, while maintaining pharmacologic selectivity of 10B to target tissues and adequate shielding of healthy tissues using a neutron absorbing material, 6LiF . An in vivo irradiation facility has been installed in the thermal column of the Moata reactor. Incident neutron flux is 10 10 n cm-2 s -l with concomitant gamma dose of 4.8 Gy h-l . Nude mice bearing human melanoma xenografts are anaesthetised and loaded into 6LiF epoxy cylinders under Specific Pathogen Free (SPF) conditions. Melanoma xenografts are located in the thigh and protrude from the cylinders; thus being exposed to the full neutron field. Healthy tissue is shielded, reducing the neutron flux to a few percent of the incident value. We have found there to be no problem associated with the concomitant whole body gamma dose within the range of exposure used for NCT. Irradiation follows i. p. or i. v. injection of 10B enriched p—borono—L—pheny1a1anine. Hcl. ( 10B/1—BPA.Hcl) at times when tumour/healthy tissue concentration ratios are optimal . Turnour size is monitored for volume changes following therapy; regression and growth delay indices are determined for different doses of 10B/ I—BPA.Hc1 and neutron fluence . These are compared with control growth curves, i e. (1) no irradiation (2) irradiation without 10 B/ I—BPA. Hcl pre—treatment.en_AU
dc.identifier.booktitle12th AINSE Radiation Biology Conference, 22-24th September 1989, Lucas Heights - AINSE Theatre : conference handbook (programme, abstracts and general information)en_AU
dc.identifier.citationBuck, S., & Allen, B. J. (1989). Regression of melanoma xenografts by neutron capture therapy. Presentation to the 12th AINSE Radiation Biology Conference, 22-24th September 1989, Lucas Heights, (pp. 30). Lucas Heights, New South Wales : AINSE.en_AU
dc.identifier.conferenceenddate1989-09-24en_AU
dc.identifier.conferencename12th AINSE Radiation Biology Conferenceen_AU
dc.identifier.conferenceplaceLucas Heights, New South Walesen_AU
dc.identifier.conferencestartdate1989-09-22en_AU
dc.identifier.pagination30en_AU
dc.identifier.placeofpublicationLucas Heights, New South Walesen_AU
dc.identifier.urihttps://apo.ansto.gov.au/handle/10238/16748en_AU
dc.language.isoenen_AU
dc.publisherAINSEen_AU
dc.subjectBiological shieldingen_AU
dc.subjectBoron compoundsen_AU
dc.subjectBoron 10 targeten_AU
dc.subjectGamma radiationen_AU
dc.subjectIn vivoen_AU
dc.subjectLithium fluoridesen_AU
dc.subjectLithium 7en_AU
dc.subjectLithium 7 reactionsen_AU
dc.subjectMelanomasen_AU
dc.subjectMiceen_AU
dc.subjectMOATA Reactoren_AU
dc.subjectNeutron capture therapyen_AU
dc.subjectNeutron fluxen_AU
dc.subjectPhenylalanineen_AU
dc.subjectRadiation dosesen_AU
dc.titleRegression of melanoma xenografts by neutron capture therapyen_AU
dc.typeConference Abstracten_AU
Files
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.63 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Conference Publications